Login Get Started
Browse
Shares
Healthcare
Biotechnology & Medical Research
Zynerba Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc logo

ZYNE - Zynerba Pharmaceuticals Inc Share News

$5.26 -0.1  -2.4%

Last Trade - 29/05/20

Sector
Healthcare
RiskRating
Speculative
Size
Small Cap
Style
Sucker Stock
Market Cap £106.3m
Enterprise Value £57.2m
Revenue £n/a
Position in Universe 3927th / 6364
Quality
Value
Momentum
StockRank™
StockReport™
Tools
Compare with... Run through checklist
Accounts
Balance sheet Income statement Cashflow statement Dividend summary
Charts News Discussions ZYNE Dividends
All News
All News Reuters News Company Announcements
BUZZ-U.S. STOCKS ON THE MOVE-StoneCo, Tuesday Morning, Zynerba Pharma
Wed 1:25pm News
BRIEF-Zynerba Says Bright Trial Achieved Clinically Meaningful Improvements From Baseline
Wed 1:14pm News
BUZZ- Zynerba: Gains on positive data from development disorder treatment study
Wed 12:27pm News
Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder
Wed 11:45am News
BUZZ-U.S. STOCKS ON THE MOVE-Alliance Data Systems, Alibaba Group, Dexcom, Can Fite Biofarma, U.S. travel firms
Tue 4:27pm News
BRIEF-Zynerba Pharmaceuticals Announces New Two-Year Data From Open Label Extension Of The Phase 2 Fab-C Trial In Patients With Fragile X
Tue 12:44pm News
BUZZ-Zynerba Pharma rises as gel improves condition of neurological disorder patients
Tue 12:33pm News
Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session
Tue 11:52am News
Zynerba Pharmaceuticals Announces Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental and Epileptic Encephalopathies (DEE) at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session
Tue 11:50am News
Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
22nd May News
Zynerba Pharmaceuticals Changes Annual Meeting of Shareholders to Virtual-Only Format in Response to COVID-19 Pandemic
21st May News
BRIEF-Zynerba Pharmaceuticals Reports First Quarter 2020 Results
11th May News
Zynerba Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights
11th May News
Zynerba Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference
10th Apr News
Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2019 Financial Results and Operational Highlights
10th Mar News
Zynerba Pharmaceuticals Announces Poster Presentations at the American Academy of Neurology (AAN) 2020 Annual Meeting
9th Mar News
Zynerba Pharmaceuticals to Present at the 32nd Annual ROTH Conference
5th Mar News
Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study Population
3rd Mar News
Zynerba Pharmaceuticals Presents Health State Utility Index Data on Severity of Fragile X Syndrome (FXS) and Diagnostic Challenges Faced by Caregivers 
3rd Mar News
BRIEF-Zynerba Pharmaceuticals Announces The Completion Of Enrollment In The Pivotal Connect-FX Trial Of Zygel In Fragile X Syndrome
26th Feb News
© Stockopedia 2020, Refinitiv, Share Data Services.
Youtube Instagram RSS
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.